59 results on '"CLAES, G."'
Search Results
2. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma
3. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma
4. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma
5. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
6. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
7. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
8. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
9. VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
10. The clinical and diagnostic role of microRNAs in ovarian carcinoma
11. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
12. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
13. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
14. Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
15. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
16. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
17. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
18. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
19. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
20. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
21. Notch3 Overexpression Is Related to the Recurrence of Ovarian Cancer and Confers Resistance to Carboplatin
22. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
23. Cleaved caspase-3 and nuclear factor- κB p65 are prognostic factors in metastatic serous ovarian carcinoma
24. Expression of the peroxisome proliferator–activated receptors– α, – β, and – γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
25. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
26. Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
27. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
28. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas
29. The clinical role of phospholipase A 2 isoforms in advanced-stage ovarian carcinoma
30. Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
31. The AP-2γ transcription factor is upregulated in advanced-stage ovarian carcinoma
32. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
33. Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors—relation to clinicopathologic variables
34. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
35. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
36. αV- and β1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
37. Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis
38. The Ideology of American Empire
39. Expression of Cell Cycle Proteins in Ovarian Carcinoma Cells in Serous Effusions—Biological and Prognostic Implications
40. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: Evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
41. MicroRNAs in Ovarian Cancer
42. Genome profiles of bilateral dysgerminomas, a unilateral gonadoblastoma, and a metastasis from a 46, XY phenotypic female
43. Improved 8-Year Survival for Patients With Stage IIIC Ovarian Cancer Operated on at Teaching Hospitals: Population-Based Study in Norway 2002
44. Corrigendum to “Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis” [Gynecol. Oncol. 89 (2003) 140–147]
45. Erratum to “expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis”: [Gynecol. Oncol. 89 (2003) 140–147]☆
46. CA 125 measured before second-look laparotomy is an independent prognostic factor for survival in patients with epithelial ovarian cancer
47. Bleomycin-ifosfamide- cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look
48. Evaluation of the Prognostic Significance of nm23/NDP Kinase Protein Expression in Cervical Carcinoma: An Immunohistochemical Study
49. Serum CA 125 Level Allows Early Identification of Nonresponders during Induction Chemotherapy
50. Is Serum CA 125 at the Time of Relapse a Prognostic Indicator for Further Survival Prognosis in Patients with Ovarian Cancer?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.